Future research in the context of prostate cancer should focus on cancers where PSA is not yet detectable, i.e., immediately after primary treatment, and on more potent vaccine technologies than DNA vaccines encoding prostate-specific antigens in combination with checkpoint blockade. The gene discussed is KLK3; the disease is prostate cancer.